Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patients
IntroductionIndividuals experiencing severe symptoms of COVID-19 are at the greatest risk of developing post-COVID lung fibrosis, which significantly impacts long-term health outcomes. This study aims to investigate the predictive potential of serum biomarkers, specifically decorin and biglycan, in...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2024.1463433/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832592616192999424 |
|---|---|
| author | Shaaf Ahmad Kaleem Maqsood Farwa Liaqat Nabila Roohi |
| author_facet | Shaaf Ahmad Kaleem Maqsood Farwa Liaqat Nabila Roohi |
| author_sort | Shaaf Ahmad |
| collection | DOAJ |
| description | IntroductionIndividuals experiencing severe symptoms of COVID-19 are at the greatest risk of developing post-COVID lung fibrosis, which significantly impacts long-term health outcomes. This study aims to investigate the predictive potential of serum biomarkers, specifically decorin and biglycan, in assessing the severity and mortality risk among COVID-19 patients.MethodsFor this study, healthy controls and COVID-19 patients (n = 240) among them 186 with moderate and 54 with severe symptoms from Ittefaq Hospital and Mayo Hospital, Lahore, Pakistan were recruited satisfying the inclusion and exclusion criteria. Patients were followed up for 2 months. Serum level of decorin and biglycan was evaluated by ELISA. One-way ANOVA and Independent sample “t”-test were applied at significance level p < 0.05 by using GraphPad Prism.ResultsDecorin levels significantly decreased from controls (43.36 ± 1.14 ng/mL) to moderate (40.24 ± 0.64 ng/mL) and severe COVID-19 patients (35.49 ± 1.00 ng/mL) (p = 0.0059). Biglycan levels increased from controls (66.15 ± 2.22 pg/mL) to moderate (70.02 ± 1.57 pg/mL) and severe patients (75.88 ± 1.97 pg/mL) (p = 0.0042). In follow-up, survivors had higher decorin (39.6 ± 0.59 ng/mL) than non-survivors (35.84 ± 1.61 ng/mL) (p = 0.0319). Biglycan levels were similar between survivors (70.98 ± 1.41 pg/mL) and non-survivors (73.99 ± 3.24 pg/mL) (p = 0.459). Higher decorin levels correlate with survival in COVID-19 patients.ConclusionSerum decorin and biglycan levels are valuable biomarkers for predicting severity and mortality in COVID-19 patients. Lower decorin and higher biglycan levels correlate with increased disease severity, emphasizing their potential to identify patients at risk for lung fibrosis and guide clinical management. |
| format | Article |
| id | doaj-art-01c558f42c0d4f0cbc32d5d66b2156be |
| institution | Kabale University |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-01c558f42c0d4f0cbc32d5d66b2156be2025-01-21T05:43:11ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-01-011110.3389/fmed.2024.14634331463433Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patientsShaaf Ahmad0Kaleem Maqsood1Farwa Liaqat2Nabila Roohi3King Edward Medical University/Mayo Hospital, Lahore, Punjab, PakistanInstitute of Zoology, University of the Punjab, Lahore, Punjab, PakistanInstitute of Zoology, University of the Punjab, Lahore, Punjab, PakistanInstitute of Zoology, University of the Punjab, Lahore, Punjab, PakistanIntroductionIndividuals experiencing severe symptoms of COVID-19 are at the greatest risk of developing post-COVID lung fibrosis, which significantly impacts long-term health outcomes. This study aims to investigate the predictive potential of serum biomarkers, specifically decorin and biglycan, in assessing the severity and mortality risk among COVID-19 patients.MethodsFor this study, healthy controls and COVID-19 patients (n = 240) among them 186 with moderate and 54 with severe symptoms from Ittefaq Hospital and Mayo Hospital, Lahore, Pakistan were recruited satisfying the inclusion and exclusion criteria. Patients were followed up for 2 months. Serum level of decorin and biglycan was evaluated by ELISA. One-way ANOVA and Independent sample “t”-test were applied at significance level p < 0.05 by using GraphPad Prism.ResultsDecorin levels significantly decreased from controls (43.36 ± 1.14 ng/mL) to moderate (40.24 ± 0.64 ng/mL) and severe COVID-19 patients (35.49 ± 1.00 ng/mL) (p = 0.0059). Biglycan levels increased from controls (66.15 ± 2.22 pg/mL) to moderate (70.02 ± 1.57 pg/mL) and severe patients (75.88 ± 1.97 pg/mL) (p = 0.0042). In follow-up, survivors had higher decorin (39.6 ± 0.59 ng/mL) than non-survivors (35.84 ± 1.61 ng/mL) (p = 0.0319). Biglycan levels were similar between survivors (70.98 ± 1.41 pg/mL) and non-survivors (73.99 ± 3.24 pg/mL) (p = 0.459). Higher decorin levels correlate with survival in COVID-19 patients.ConclusionSerum decorin and biglycan levels are valuable biomarkers for predicting severity and mortality in COVID-19 patients. Lower decorin and higher biglycan levels correlate with increased disease severity, emphasizing their potential to identify patients at risk for lung fibrosis and guide clinical management.https://www.frontiersin.org/articles/10.3389/fmed.2024.1463433/fullCOVID-19decorinbiglycanproteoglycanlung fibrosis |
| spellingShingle | Shaaf Ahmad Kaleem Maqsood Farwa Liaqat Nabila Roohi Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patients Frontiers in Medicine COVID-19 decorin biglycan proteoglycan lung fibrosis |
| title | Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patients |
| title_full | Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patients |
| title_fullStr | Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patients |
| title_full_unstemmed | Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patients |
| title_short | Serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in COVID-19 patients |
| title_sort | serum decorin and biglycan levels as predictive biomarkers for lung fibrosis severity and mortality risk in covid 19 patients |
| topic | COVID-19 decorin biglycan proteoglycan lung fibrosis |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2024.1463433/full |
| work_keys_str_mv | AT shaafahmad serumdecorinandbiglycanlevelsaspredictivebiomarkersforlungfibrosisseverityandmortalityriskincovid19patients AT kaleemmaqsood serumdecorinandbiglycanlevelsaspredictivebiomarkersforlungfibrosisseverityandmortalityriskincovid19patients AT farwaliaqat serumdecorinandbiglycanlevelsaspredictivebiomarkersforlungfibrosisseverityandmortalityriskincovid19patients AT nabilaroohi serumdecorinandbiglycanlevelsaspredictivebiomarkersforlungfibrosisseverityandmortalityriskincovid19patients |